Re: KB note

Hi Elizabeth,

Thanks a lot for the information. It seems to fit in the broad 
"cholinergic hypothesis"

http://www.ncbi.nlm.nih.gov/pubmed/16918347

It's interesting to know, as you pointed out, that the clinical trials 
for the same drug are in different phases in different countries. It 
would be great if we can integrate such clinical trial data across 
different countries.

Best,

-Kei

Elizabeth Wu wrote:
> Hi Kei,
>
> There is an entry in the Drugs in Clinical Trials section of Alzforum on
> Huperzine A http://www.alzforum.org/drg/drc/detail.asp?id=53. The drug is
> currently in Phase IV clinical trial in China and phase II in the US.  Its
> proposed actions are linked to many of the AD hypotheses, and I would think
> that if there are sources on research on herbs that could provide more
> insight, it would be of interest to the community.
>
> Best,
>
> Elizabeth
>
> Elizabeth Wu
> Alzheimer Research Forum
>  
>
> -----Original Message-----
> From: public-semweb-lifesci-request@w3.org
> [mailto:public-semweb-lifesci-request@w3.org] On Behalf Of
> kc28@email.med.yale.edu
> Sent: Sunday, May 25, 2008 10:41 PM
> To: Tim Clark
> Cc: M. Scott Marshall; public-semweb-lifesci@w3.org
> Subject: Re: KB note
>
>
> Hi Tim et al.,
>
> I think it would be great if more details about SWAN can be added. The HCLS
> ecosystem consists of scientists, patients, doctors, government agencies,
> publishers, etc. Creating/maintaining a balance in this digital age across
> national boundaries is challenging/interesting.
>
> Speaking of national boundaries, I wonder if alternative medicine (e.g.,
> herbal
> medicine) would also be of interest to this community. For example,
> Huperzine
> is a drug derived from the herb Huperzia serrata. I also wonder if there are
> hypotheses regarding the study of herbs in the possible treatment of
> neurological diseases.
>
> Thanks,
>
> -Kei
>
>
> Quoting Tim Clark <twclark@nmr.mgh.harvard.edu>:
>
>   
>> Hi Scott,
>>
>> Your KB note lists no details about SWAN - we would like to see them
>> included.  I'll forward something to you in a separate email later
>> today.
>>
>> Best
>>
>> Tim
>>
>> Tim Clark
>> Director of Informatics, MassGeneral Institute for Neurodegenerative
>> Disease
>> Instructor in Neurology, Harvard Medical School
>> 617-947-7098 (mobile)
>>
>> On May 23, 2008, at 6:59 PM, M. Scott Marshall wrote:
>>
>>     
>>> The KB note is ready for a last round of feedback and corrections.
>>> We have until the end of the month to publish so please be speedy
>>> with feedback. You can view the Editor's working draft at:
>>>       
>> http://www.w3.org/2001/sw/hcls/notes/kb/
>>     
>>> Thanks,
>>> Scott
>>>
>>> --
>>> M. Scott Marshall
>>> tel. +31 (0) 20 525 7522
>>> http://staff.science.uva.nl/~marshall
>>> http://adaptivedisclosure.org
>>>
>>>
>>>
>>>
>>>       
>>
>>
>>     
>
>
>
>

Received on Tuesday, 27 May 2008 20:43:21 UTC